कृपया अन्य खोज का प्रयास करें
चिन्ह | एक्सचेंज | करेंसी | ||
---|---|---|---|---|
BMRN | NASDAQ | USD | रियल टाइम | |
1BMRN | मिलान | EUR | रियल टाइम | |
BMRN | विएना | EUR | रियल टाइम |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Robert J. Hombach | 57 | 2017 | Independent Director |
Elizabeth McKee Anderson | 66 | 2019 | Independent Director |
Elaine J. Heron | 75 | 2002 | Independent Director |
Richard A. Meier | 63 | 2006 | Independent Chairman of the Board |
Mark J. Alles | 64 | 2022 | Independent Director |
Jean-Jacques Bienaime | 70 | 2005 | Director |
Dennis J. Slamon | 74 | 2014 | Independent Director |
Maykin Ho | 70 | 2021 | Independent Director |
V. Bryan Lawlis | 71 | 2007 | Independent Director |
David E. I. Pyott | 70 | 2016 | Independent Director |
Willard H. Dere | 69 | 2016 | Independent Director |
Athena Maria Countouriotis | 51 | 2023 | Independent Director |
Mark Joseph Enyedy | 59 | 2023 | Independent Director |
Barbara W. Bodem | 55 | 2023 | Independent Director |
Alexander Hardy | 55 | 2023 | President, CEO & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है